Screener
Rhythm Pharmaceuticals, Inc. RYTM Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | 2025 |
|---|---|---|
| Interest expense | (4,583) | (5,409) |
| Interest income | 3,554 | 3,639 |
| Total other income (expense), net | (2,733) | (2,414) |
| Loss before income taxes | (55,094) | (49,418) |
| Provision for income taxes | 545 | 80 |
| Net loss | $(55,639) | $(49,498) |
| Accrued dividends on convertible preferred stock | (1,104) | (1,322) |
| Net loss attributable to common stockholders | $(56,743) | $(50,820) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s pre-tax income?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported pre-tax income of -$55.09M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s pre-tax income changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s pre-tax income decreased by 11.5% year-over-year, from -$49.42M to -$55.09M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s pre-tax income?
- Over 2 years (2023 to 2025), Rhythm Pharmaceuticals, Inc.'s pre-tax income has grown at a 3.2% compound annual growth rate (CAGR), from -$184.11M to -$196.04M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude